These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23539459)

  • 1. Effect of VEGF and anti-VEGF compounds on retinal pigment epithelium permeability: an in vitro study.
    Campa C
    Eur J Ophthalmol; 2013; 23(5):690-6. PubMed ID: 23539459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y; Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S; Adelman RA; Rizzolo LJ
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect comparison of ranibizumab and sodium pegaptanib on the retinal pigment epithelium ablation size in the treatment of age-related macular degeneration].
    Sin M; Jakubcová M; Chrapek O; Pracharová Z; Simicák J; Rehák J
    Cesk Slov Oftalmol; 2012 May; 68(2):57-60. PubMed ID: 22913867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
    Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
    Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
    Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
    Chiang A; Chang LK; Yu F; Sarraf D
    Retina; 2008 Oct; 28(9):1265-9. PubMed ID: 18628724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
    Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
    Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sodium pegaptanib and ranibizumab in the treatment of the retinal pigment layer ablation in a patient with age-related macular degeneration--a case report].
    Sín M; Simicák J; Pracharová Z; Rehák J
    Cesk Slov Oftalmol; 2010 Jul; 66(3):138-41. PubMed ID: 21137477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of somatostatin on human retinal pigment epithelial cells permeability.
    Fonollosa A; Valcarcel M; Salado C; Pereiro X; Vecino E
    Exp Eye Res; 2019 Jul; 184():15-23. PubMed ID: 30978347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.